Eyepoint Stock Based Compensation To Revenue from 2010 to 2024
| EYPT Stock | USD 8.25 0.21 2.48% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.26200617 | Current Value 0.35 | Quarterly Volatility 0.42641578 |
Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 440.8 K, Interest Expense of 1.6 M or Total Revenue of 48.3 M, as well as many indicators such as Price To Sales Ratio of 18.09, Dividend Yield of 0.0 or PTB Ratio of 3.13. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
Eyepoint | Stock Based Compensation To Revenue |
Latest Eyepoint Pharmaceuticals' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Eyepoint Pharmaceuticals over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Eyepoint Pharmaceuticals' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyepoint Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Eyepoint Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.45 | |
| Geometric Mean | 0.33 | |
| Coefficient Of Variation | 94.32 | |
| Mean Deviation | 0.30 | |
| Median | 0.34 | |
| Standard Deviation | 0.43 | |
| Sample Variance | 0.18 | |
| Range | 1.4346 | |
| R-Value | (0.17) | |
| Mean Square Error | 0.19 | |
| R-Squared | 0.03 | |
| Significance | 0.54 | |
| Slope | (0.02) | |
| Total Sum of Squares | 2.55 |
Eyepoint Stock Based Compensation To Revenue History
About Eyepoint Pharmaceuticals Financial Statements
Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.26 | 0.35 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.